|
|||||
|
|
Risk factors and model for predicting toxicity‐related treatment discontinuation in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor–targeted therapy: Results from the International Metastatic Renal Cell Carcinoma Database Consortium |
|
| Authors: | Marina D. Kaymakcalan PharmD Wanling Xie MS Laurence Albiges MD Scott A. North MD Christian K. Kollmannsberger MD Martin Smoragiewicz MD Nils Kroeger MD J. Connor Wells MD Sun‐Young Rha MD Jae Lyun Lee MD Rana R. McKay MD André P. Fay MD Guillermo De Velasco MD Toni K. Choueiri MD |
| Affiliation: | 1. Dana‐Farber Cancer Institute, Boston, Massachusetts;2. Department of Medicine, Cross Cancer Institute, Edmonton, Canada;3. British Columbia Cancer Agency, Vancouver, Canada;4. Tom Baker Cancer Center, University of Calgary, Calgary, Alberta, Canada;5. Yonsei University College of Medicine, Seoul, Korea;6. Asan Medical Center, Seoul, Korea |
| Abstract: | |
| Keywords: | International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) model renal cell carcinoma risk factors toxicity treatment discontinuation VEGF‐targeted therapies |